局限性肝内胆管癌的管理：究竟什么才是“证据”？ - Suppr

Suppr

超能文献

Management of Localized Intrahepatic Cholangiocarcinoma: What Exactly is the 'Evidence'?

作者信息

Ocuin Lee M

机构信息

, Cleveland, OH, USA.

出版信息

Ann Surg Oncol. 2024 Nov;31(12):7676-7678. doi: 10.1245/s10434-024-16023-z. Epub 2024 Aug 5.

DOI:10.1245/s10434-024-16023-z

PMID:39103689

Abstract

摘要

相似文献

Management of Localized Intrahepatic Cholangiocarcinoma: What Exactly is the 'Evidence'?局限性肝内胆管癌的管理：究竟什么才是“证据”？

Ann Surg Oncol. 2024 Nov;31(12):7676-7678. doi: 10.1245/s10434-024-16023-z. Epub 2024 Aug 5.

ASO Author Reflections: ICC PRS Score: Clinically Useful Tool to Predict Post-recurrence Survival and Guide Management of Recurrent Intrahepatic Cholangiocarcinoma.ASO作者反思：ICC PRS评分：预测复发后生存及指导复发性肝内胆管癌管理的临床实用工具。

Ann Surg Oncol. 2024 Jul;31(7):4458-4459. doi: 10.1245/s10434-024-15269-x. Epub 2024 Apr 11.

Liver transplantation for intrahepatic and perihilar cholangiocarcinoma: Current and future.肝内和肝门周围胆管癌的肝移植：现状与未来

Hepatobiliary Pancreat Dis Int. 2020 Apr;19(2):101-102. doi: 10.1016/j.hbpd.2020.02.008. Epub 2020 Feb 28.

ASO Author Reflections: Radical Resection After Neoadjuvant Therapy for Intrahepatic Cholangiocarcinoma-Emerging Technologies in Comprehensive Treatment Strategies.ASO作者反思：肝内胆管癌新辅助治疗后的根治性切除——综合治疗策略中的新兴技术

Ann Surg Oncol. 2024 Oct;31(10):6573-6575. doi: 10.1245/s10434-024-15896-4. Epub 2024 Jul 24.

Cholangiocarcinoma.胆管癌。

Surg Clin North Am. 2024 Dec;104(6):1281-1293. doi: 10.1016/j.suc.2024.04.003. Epub 2024 May 10.

Update on the management of cholangiocarcinoma.胆管癌管理的最新进展。

Dig Dis. 2014;32(5):570-8. doi: 10.1159/000360507. Epub 2014 Jul 14.

Surgical treatment for intrahepatic cholangiocarcinoma.肝内胆管癌的外科治疗

Clin J Gastroenterol. 2014 Apr;7(2):87-93. doi: 10.1007/s12328-014-0460-z. Epub 2014 Feb 15.

Cholangiocarcinoma.胆管癌

Surg Pathol Clin. 2018 Jun;11(2):403-429. doi: 10.1016/j.path.2018.02.005.

[Clinical pathology of cholangiocarcinoma (intrahepatic bile duct cancer)].胆管癌（肝内胆管癌）的临床病理学

Nihon Geka Hokan. 1995 Nov 1;64(6):129-30.

Surgical treatment of intrahepatic cholangiocarcinoma: A letter in response to "Is liver transplantation a viable option for the treatment of intrahepatic cholangiocarcinoma".肝内胆管癌的外科治疗：一封回应“肝移植是治疗肝内胆管癌的可行选择吗”的信

J Surg Oncol. 2021 Oct;124(5):908-909. doi: 10.1002/jso.26577. Epub 2021 Jun 15.

本文引用的文献

Has Management of Intrahepatic Cholangiocarcinoma Evolved with the Evidence? Trends and Practice Patterns from the National Cancer Database.肝内胆管癌的治疗是否随着循证医学证据的发展而变化？来自国家癌症数据库的趋势和实践模式。

Ann Surg Oncol. 2024 Oct;31(10):6551-6563. doi: 10.1245/s10434-024-15724-9. Epub 2024 Jul 23.

Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.度伐利尤单抗或安慰剂联合吉西他滨和顺铂治疗晚期胆道癌（TOPAZ-1）：一项随机 3 期研究的更新总生存期数据。

Lancet Gastroenterol Hepatol. 2024 Aug;9(8):694-704. doi: 10.1016/S2468-1253(24)00095-5. Epub 2024 May 29.

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.度伐利尤单抗联合吉西他滨和顺铂治疗晚期胆道癌。

NEJM Evid. 2022 Aug;1(8):EVIDoa2200015. doi: 10.1056/EVIDoa2200015. Epub 2022 Jun 1.

Improved Clinical Staging System for Localized Pancreatic Cancer Using the ABC Factors: A TAPS Consortium Study.基于 ABC 因素的改良局部胰腺癌临床分期系统：TAPS 联盟研究。

J Clin Oncol. 2024 Apr 20;42(12):1357-1367. doi: 10.1200/JCO.23.01311. Epub 2024 Feb 5.

Gemcitabine with Cisplatin Versus Hepatic Arterial Infusion Pump Chemotherapy for Liver-Confined Unresectable Intrahepatic Cholangiocarcinoma.吉西他滨联合顺铂与经肝动脉化疗泵灌注化疗治疗不可切除的局限性肝内胆管细胞癌的比较

Ann Surg Oncol. 2024 Jan;31(1):115-124. doi: 10.1245/s10434-023-14409-z. Epub 2023 Oct 9.

NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma.NEO-GAP：吉西他滨、顺铂和 Nab-紫杉醇新辅助治疗可切除高危肝内胆管细胞癌的单臂、II 期可行性试验。

Ann Surg Oncol. 2023 Oct;30(11):6558-6566. doi: 10.1245/s10434-023-13809-5. Epub 2023 Jun 27.

Role of genomics in intrahepatic cholangiocarcinoma for liver-directed therapy.基因组学在肝内胆管癌肝靶向治疗中的作用。

Surgery. 2023 Aug;174(2):425-427. doi: 10.1016/j.surg.2023.04.009. Epub 2023 May 13.

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.帕博利珠单抗联合吉西他滨和顺铂与单纯吉西他滨和顺铂治疗晚期胆道癌患者的比较（KEYNOTE-966）：一项随机、双盲、安慰剂对照、3 期临床试验。

Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16.

Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians.肝内胆管癌治疗进展：临床医生当前及未来治疗前景概述

CA Cancer J Clin. 2023 Mar;73(2):198-222. doi: 10.3322/caac.21759. Epub 2022 Oct 19.

A nationwide analysis of clinical trial participation for common hepato-pancreato-biliary malignancies demonstrates survival advantages for subsets of trial patients but disparities in and infrequency of enrollment.一项针对常见肝胆管癌临床试验参与情况的全国性分析表明，试验患者亚组的生存优势，但在入组率和入组频率方面存在差异。

HPB (Oxford). 2022 Aug;24(8):1280-1290. doi: 10.1016/j.hpb.2021.12.022. Epub 2022 Jan 6.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验